AKL Research and Development (AKLRD) has recently completed a Phase 2a, 28-day 150 patient, trial of oral APPA in osteoarthritis (OA) of the knee
The data from this Phase 2a trial adds considerably to our understanding of APPA. It advances our ability to select the patients most likely to benefit from APPA. Key Findings from the trial:
The data generated warrants a longer trial duration with multiple doses in a trial population of more severe OA, this also being the target commercial population